Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: RNA sequencing of MC38 mouse tumor tissue with and without drug over time

PROVIDER: PRJNA477557 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7414690_1.fastq.gz	Fastqsanger.gz
	SRR7414690_2.fastq.gz	Fastqsanger.gz
	SRR7414700_1.fastq.gz	Fastqsanger.gz
	SRR7414700_2.fastq.gz	Fastqsanger.gz
	SRR7414710_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 171

Similar Datasets

Project description:RNA sequencing of EMT6 syngeneic mouse tumor tissue with and without drug over time

| PRJNA478198 | ENA

Project description:RNA sequencing of B16F0 syngeneic mouse tumor tissue with and without drug over time

| PRJNA478383 | ENA

Project description:RNA sequencing of MC38 mouse tumor tissue with escalating drug dose

| PRJNA477829 | ENA

Project description:RNA sequencing of MC38 mouse tumor tissue treated +/- drug and +/- immune cell depletion

| PRJNA477845 | ENA

RNA-sequencing on sorted infiltrating CD8 T cells from vehicle or JHU083, pro-drug of 6-Diazo-5-oxo-L-norleucine (glutamine antagonist) treated MC38 (colon cancer) tumor bearing mice

Project description:RNA-sequencing was performed on sorted CD11b-CD11c-B220-CD45+TCRbeta+CD44+CD8+ TIL from vehicle or JHU083 treated MC38 tumor-bearing mice with or without JHU083, pro-drug of 6-Diazo-5-oxo-L-norleucine (glutamine antagonist) treatment for expression profiling

2020-02-24 | GSE120345 | GEO

Transcriptional response to vanoxerine in vivo treatments in MC38 colorectal tumors

Project description:Murine colorectal cancer MC38 cells were injected in the flank of C57BL/6 mice to form tumor grafts over 7 days. Tumor-bearing mice were treated with daily injections of vanoxerine (25mg/kg) or vehichle control (saline) over 10 consecutive days. Tumors were excised and RNA sequencing profiling was performed on both experimental condition.

2022-07-13 | GSE207032 | GEO

Single cell TCR-seq profiling of T cells isolated from LNs of MC38 tumor-bearing mice

Project description:We investigate the single-cell landscape of the inflammatory mouse tumor model MC38, a C57BL/6 tumor cell line derived from colon adenocarcinoma. MC38 (diluted in HBSS and matrigel) was inoculated in the right unilateral flank (in the border of positions B2 and B3) of C57BL/6 mice (ref Study 16-3384 AV). Draining lymph nodes were taken one day after group-out (average 150-250 mm3 tumor size at day 0), approximately 14-19 days. Draining lymph nodes were dissociated and flow sorted accordingly to obtain the cells for 10x Chromium 5' Gene Expression Profiling and TCR sequencing.

2022-08-16 | E-MTAB-9734 | biostudies-arrayexpress

Project description:MC38 Mouse Tumor Model Characterization

| PRJNA551473 | ENA

Regulatory T cells in the Tumor Microenvironment Display a Unique Chromatin Accessibility Profile (ATAC-Seq)

Project description:Regulatory T cells (Tregs) are a suppressive CD4+ T cell population that limit the anti-tumor immune response. In this study, we analyzed the chromatin accessibility of Tregs in the murine tumor microenvironment (TME) to identify tumor-specific accessible peaks and if these are altered over time in the tumor microenvironment, with or without anti-PD1 immunotherapy. We found that Tregs have a more distinct chromatin accessibility signature in the TME compared to Tregs in the periphery than within location over time in the models we accessed. This distinct tumor Treg chromatin accessibility profile highlights reduced accessibility at loci important for an CD4+ conventional T cell (CD4+ Foxp3—) effector phenotype and reinforcement of a suppressive phenotype. Analysis of chromatin accessibility in Tregs in B16 and MC38 tumor models indicated similar regulation independent of tumor type, indicating a tumor-derived Treg effector signature in the models we accessed. We also found that Tregs do not alter their transcriptome nor chromatin accessibility following immunotherapy. We conclude that chromatin accessibility in Tregs is altered in the TME, but is otherwise remarkably stable and appears unaltered by tumor type, over time, or following immunotherapy.

2025-02-26 | GSE246700 | GEO

Regulatory T cells in the Tumor Microenvironment Display a Unique Chromatin Accessibility Profile (RNA-Seq)

2025-02-26 | GSE246701 | GEO